Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma

Cancer Research

Volumn 75, Issue 20, 2015, Pages 4384-4397

  Zhao, Jian Jun ^a   Chu, Zhang Bo ^a,b   Hu, Yu ^b   Lin, Jianhong ^a   Wang, Zhongqiu ^a   Jiang, Meng ^a   Chen, Ming ^a   Wang, Xujun ^c   Kang, Yue ^a   Zhou, Yangsheng ^a   Chonghaile, Triona Ni ^a   Johncilla, Melanie E ^d   Tai, Yu Tzu ^a   Cheng, Jin Q ^e   Letai, Antony ^a   Munshi, Nikhil C ^a,f   Anderson, Kenneth C ^a   Carrasco, Ruben D ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c TONGJI UNIVERSITY   (China)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MICRORNA 221; MICRORNA 222; PROTEIN BAK; PROTEIN BAX; PUMA PROTEIN; 3' UNTRANSLATED REGION; APOPTOSIS REGULATORY PROTEIN; BAK1 PROTEIN, HUMAN; BBC3 PROTEIN, HUMAN; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; ONCOPROTEIN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL VIABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; PROPENSITY SCORE; PROTEIN DEGRADATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BINDING SITES; CELL LINE, TUMOR; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; MULTIPLE MYELOMA; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945533111     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0457     Document Type: Article

References (49)

1. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, et al. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013;11:11-7.
2. Villunger A, Michalak EM, Coultas L, Mullauer F, BockG, AusserlechnerMJ, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
3. Sharma S, Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 2008;112:1338-45.
4. Fisher C, Coleman T, Plant N. Probabilistic orthology analysis of the ATPbinding cassette transporters: implications for the development of multiple drug resistance phenotype. Drug Metab Dispos 2012;40:1397-402.
5. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001;15: 264-71.
6. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408:86-9.
7. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107:823-6.
8. Loffler D, Brocke-Heidrich K, PfeiferG, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-3.
9. Kim YK, Yu J,Han TS, Park SY, Namkoong B, KimDH, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 2009;37:1672-81.
10. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, et al. Identification of microRNA expression patterns and definition of a micro- RNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-6.
11. Terasawa K, Ichimura A, Sato F, Shimizu K, Tsujimoto G. Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J 2009;276:3269-76.
12. Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res 2014;74: 1801-13.
13. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115:2630-9.
14. Meier J, Hovestadt V, ZapatkaM, Pscherer A, Lichter P, Seiffert M. Genomewide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP. RNA Biol 2013;10:1018-29.
15. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82.
16. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334:1129-33.
17. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008;283:31079-86.
18. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003;31:271-82.
19. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72.
20. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid- induced apoptosis. Cell Death Differ 2002;9:6-19.
21. Saha MN, Jiang H, Chang H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Cancer Biol Ther 2010;10:567-78.
22. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005;436:740-4.
23. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629-37.
24. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008;27:S71-83.
25. Le Pennec S, Savagner F. [MiRNAs in follicular thyroid tumors]. Presse Med 2011;40:683-9.
26. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, Del Basso De Caro M, et al. miR-221/222 overexpression in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 2012;31:858-68.
27. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010;25:1674-80.
28. Navarro A, Marrades RM, Vinolas N, Quera A, Agusti C, Huerta A, et al. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009;76: 162-9.
29. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126:73-80.
30. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2010;15:1593-602.
31. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010;10:367.
32. Pineau P, Volinia S, McJunkin K,Marchio A, Battiston C, Terris B, et al. miR- 221 overexpression contributes to liver tumorigenesis. Proc Natl Acad SciU S A 2010;107:264-9.
33. Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer 2010;9:123.
34. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007;121:1156-61.
35. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008;68:2773-80.
36. Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH, Tsai MM, et al. miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med 2011;40:560-6.
37. Liu X, Yu J, Jiang L,Wang A, Shi F, Ye H, et al. MicroRNA-222 regulates cell invasion by targetingmatrix metalloproteinase 1 (MMP1) andmanganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics 2009;6:131-9.
38. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-24.
39. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26:3699-708.
40. Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010;37: 1621-6.
41. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, et al. AntimicroRNA- 222 (anti-miR-222) and -181B suppress growth of tamoxifenresistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011;286:42292-302.
42. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, et al. miR-221/ 222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-tomesenchymal transition in breast cancer. Sci Signal 2011;4:pt5.
43. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009; 48:521-31.
44. DiMartino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55.
45. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993;81:128-35.
46. Ocio EM, Fernandez-Lazaro D, San-Segundo L, Lopez-Corral L, Corchete LA, Gutierrez NC, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia 2015;29:705-14.
47. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17:4125-35.
48. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011;18:2035-41.
49. Lin Q, Mao W, Shu Y, Lin F, Liu S, Shen H, et al. A cluster of specified microRNAs in peripheral blood as biomarkers formetastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res ClinOncol 2012;138:85-93.